Navigation Links
Catalent Pharma Solutions Breaks Ground On A Major Expansion Of Its Winchester, Kentucky Controlled Release Manufacturing Facility
Date:6/12/2013

SOMERSET, N.J., June 12, 2013 /PRNewswire/ -- Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky. The company is to invest nearly $35 million to expand the 100,000 square-foot facility by almost 80,000 square feet of modern manufacturing space, and will add as many as 90 new employees at the expanded site. Construction will commence on June 12, 2013 with a ceremony led by Kentucky Governor Steve Beshear and Catalent President and CEO John Chiminski. Catalent expects to complete the expansion by October 2014, and will welcome customers to tour the facility at that time.

The Governor of the Commonwealth of Kentucky, Steve Beshear, made the following statement, "Catalent is making tremendous strides forward in Winchester, and we're excited to see such success for a global company in the Commonwealth. The numbers speak for themselves, with 90 new jobs and $35 million in investment, but this also shows the level of confidence that Catalent has in Kentucky's high quality workforce."

Opened in 1992, Catalent's Winchester facility has evolved into one of the industry's premier sites for advanced oral controlled-release drug formulation and manufacturing, launching over 100 products for Catalent's pharmaceutical and consumer health customers. As industry demand for innovative dose forms continues to increase, Catalent is responding through expansion of its manufacturing premises and continuous improvement of equipment and workflows. 

"Catalent is a fully integrated formulation, regulatory, and manufacturing
'/>"/>

SOURCE Catalent Pharma Solutions
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalent Pharma Solutions, Inc. Announces Increase In Tender Cap For Its Cash Tender Offer For Its 9-1/2%/10-1/4% Senior PIK-Election Notes Due 2015
2. Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015
3. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
4. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
5. GDS International Leads the Way for the Pharmaceutical Industry at its Upcoming NGP DD 30 Summit in Madrid
6. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
7. Royalty Pharma Files Judicial Review Proceedings
8. Pointlogic and Kantar Media Announce Dedicated Communication Planning Solution for Pharmaceutical Industry
9. The Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis
10. NovoBioPharma, Partnership of Top Life Science Experts, Launches
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Ga., May 3, 2011 Precyse , ... and technologies, announces the general availability of ... information management platform available today. PrecyseCode is driven ... voice, converting it to text and transforming it ...
... May 3, 2011 HistoRx, Inc., announced today ... researchers interested in using AQUA® technology.  HistoRx,s proprietary ... biomarkers, including measurement of protein concentration with sub-cellular ... microarrays.  These highly quantitative, standardized and reproducible results ...
Cached Medicine Technology:Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 2Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 3Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 4Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 5Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management 6HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available 2HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available 3
(Date:4/22/2014)... MD, April 22, 2014: The Association for Molecular ... The Journal of Molecular Diagnostics on recommendations ... baccalaureate and master,s levels of education. The report ... Curriculum Task Force of the AMP Training and ... critical need of educating future medical laboratory scientists ...
(Date:4/22/2014)... German . ... but their mode of action is complex: In low ... behavior, while at high concentrations they can cause "oxidative ... how redox signaling unfolds in single cells and organelles ... developed jointly by the teams of LMU Professor Martin ...
(Date:4/22/2014)... we all seem to know who we say is neurotic ... isn,t unable to act but simply doesn,t want to., ... study of nearly 4,000 college students in 19 countries has ... decisions and moving forward with life. Turns out that when ... just don,t like it as much as non-neurotics. Therefore persuasive ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
(Date:4/22/2014)... like toddlers, but their total brain size suggests ... or fox squirrel, according to a new study ... from orangutans to zebra finches. , Scientists at ... than two-dozen other research institutions collaborated on this ... defined in the study as the ability to ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... MedCom USA, Inc.,(OTC Bulletin Board: EMED), a leading ... for the healthcare industry,has signed a distribution agreement ... force, the product line of MedCom USA.,MedCom,s products ... options which include Credit/Debit, Easy Pay and Check,Guarantee/EFT ...
... Heart Association says high blood sugar condition linked to ... -- A national effort is needed to deal with ... says an American Heart Association scientific statement released Monday. ... about the condition, also known as hyperglycemia, in people ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... president of clinical research. In this newly,created position, ... and,oversight of Rigel,s clinical research programs in rheumatoid ... syk kinase,inhibitor, is expected to enter advanced Phase ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS; ... the United States that operates Beijing Liang,Fang Pharmaceutical ... Pharmaceutical,Co., Ltd. both of which are pharmaceutical companies ... that it has raised $5 million in,a private ...
... NEW YORK, Feb. 26 , WHO: New York Lt. Gov. David A. Paterson, along with stem ... R. Lyon, M.D., will be the keynote speakers at the 3rd ... p.m. on Tuesday, February 26 ... Trianon Ballroom 1335 Avenue ...
... BMR, TORONTO, Feb. 26 /PRNewswire-FirstCall/ ... dedicated to the development and,commercialization of ... II data,on the Company,s Neuradiab product ... glioblastoma multiforme (GBM) were published in ...
Cached Medicine News:Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 2Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 3Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 4Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 3Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 2Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 3Health News:MEDIA ADVISORY: New York Lt. Gov. David Paterson and Stem Cell Experts to Participate in 3rd Annual Stem Cell Summit 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 3Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 4
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... adjustable height permits optimal leg position for the ... a cast with the foot/ankle at 90 degrees ... the tongue of the stand. Stockinette is pulled ... plaster/fiberglass is used in a routine fashion. The ...
... Techno-Aide provides the highest level of ... quality lead protective eyewear. Consistent ... tolerance allowed. Mfg supervised by Licensed ... lens meet or exceed standards for ...
Medicine Products: